GDF-15 levels and CVDs. These experiments conclusively demonstrate that GDF-15 levels link to the adverse cardiovascular events across a spectrum of CVD conditions including heart failure (HF), chest pain, acute coronary syndromes (ACS), stable ischemic heart disease, stroke, and atrial fibrillation. [5] [6] [7] [8] The potential ability of GDF-15 may attribute to the earlier diagnosis, risk stratification and prognosis assessment.
However, no systematic review and meta-analysis have analyzed the available data pertaining to the association between GDF-15 levels and
CVDs or all-cause mortality. Hence, we perform a meta-analysis for the purpose of qualitatively and quantitatively assessing the relationship between GDF-15 levels and CVDs or all-cause mortality.
| MATERIALS AND METHODS

| Literature Search
Following the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis guideline, we searched PubMed and ISI Web of Science databases from January 1, 1950 to December 31, 2017 for the terms "growth differentiation factor-15" or "macrophage inhibitory cytokine 1"or "placental transforming growth factor beta" or "nonsteroidal anti-inflammatory drug-activated gene-1" or "prostatederived factor" and "cardiovascular disease" or "coronary heart disease" or "ischemic heart disease" or "myocardial infarction" or "heart failure" or "stroke" or "all-cause mortality"or "acute coronary syndrome" or "troponin." The retrieval process was independently completed by two authors (S. Xie and L. Liu). In addition, we also retrieved the reference list of the selected studies and recent reviews for obtaining further information. The literature search was restricted to human studies and published in English language.
| Inclusion and exclusion criteria
Studies were eligible for inclusion if they met the following criteria:
(a) prospective cohort study, (b) follow-up duration of at least 3 months, (c) reported at least one of the interesting outcomes: major cardiovascular endpoints (cardiovascular death, myocardial infarction, stroke, and HF) or all-cause mortality, (d) provided relative risk (RR) or hazard ratio (HR) with 95% confidence interval (CI) for GDF-15 levels comparing the highest levels to the lowest or definite increases for risk factor as a continuous variable (data after logarithmic transformation). Studies were excluded if the study design was review articles, case-controlled studies ,retrospective cohort studies, commentaries, editorials, or case report; studies concerning ecological ,animal, or cell culture, genetic variation in GDF-15 relevant genes were not selected;
we also excluded the study population based on non-adult.
| Data extraction
Two investigators (S. Xie and L. Liu) performed the relevant data extraction with discrepancies reconciled through deliberation with a third investigator (L. Lu).The information was extracted as follows:
authors, publication year, sample size, characteristics of the baseline population, mean age of the participants, study location, mean levels of GDF-15, detective method, follow-up, study endpoints, total number of related events, RR or HR with 95% CI, covariates adjusted for in multivariable analyses. The data from different sub-cohort of the same study was extracted separately.
| Assessment of study quality
According to the Newcastle-Ottawa quality assessment scale (for cohort study), the assessment of including study quality was performed following three aspects: participants selection, comparability of groups, and ascertainment of outcome. A study can be awarded a maximum of one score for each numbered item within the selection.
A maximum of two scores can be given for comparability and selection. Higher scores of studies represented better quality. 3 | RESULTS
| Statistical analyses
| Identification of studies
The procedures of literature retrieval and selection were present in Figure 1 . We initially retrieved 886 relevant publications from the PubMed and ISI Web of Science electronic databases. The majority of these were excluded after screening the titles or abstracts, because of editorials/reviews/case reports/cross-sectional design or not related.
Twenty studies did not provide interesting outcomes, 18 articles were excluded because the data provided were insufficient or unavailable, one study was excluded because of duplicate report on the same study population, and one study follow-up duration was less than 3 months. Finally, 29 studies were selected in our meta-analysis. 26 atrial fibrillation (AF) 33 and intensive care unit patients. 35 The mean age of the subjects ranged from 42 to 79 years. The median follow-up duration ranged from 0.25 to 11.3 years. (Figure 2A ). Moreover, when regarded GDF-15 level as a continuous variable, the pooled HR for cardiovascular mortality from six studies was 2.11 (95% CI, 1.57-2.66) per log-unit ng/L increment using a random effect model. ( Figure 2B ). Figure 2C showed the pooled HR for all-cause mortality comparing the highest GDF-15 category with lowest of GDF-15 level (HR, 2.54; 95% CI, 2.07-3.01). When GDF-15 concentration increased one logunit ng/L, 2.7-fold of the risk of all-cause mortality correspondingly varied (HR, 2.70; 95% CI, 2.29-3.12 ( Figure 2D ).
| Study characteristics
| GDF-15 and the risk of all-cause mortality
| GDF-15 and the risk of complex adverse outcome
We observed that GDF-15 concentration was associated with an increased risk of complex adverse outcome (HR, 1.80; 95% CI, 1.38-2.23), when pooling data from six studies reporting the estimates as categorical 
| Heterogeneity measurement
As the heterogeneity inspection tools, meta-regression, analysis and sensitivity analysis were carried out aimed at exploring the potential sources of heterogeneity on all-cause mortality regarding GDF-15 as a categorical variable or continuous variable in our study. The detailed results were displayed in the Figure 3A , B. Meta-regression analysis was executed to exploit the heterogeneity stratified by such feasible causes, sample size, baseline population duration of follow-up, assay method, and adjustment. In evidence, the aforementioned four factors were unable to strike significant heterogeneity, but whether to adjust the confounding variables may be one of the sources of All-cause mortality Per SD 2.0 (1.6-2.5) Age, hypertension, diabetes, previous AMI, previous heart failure, heart rate and sBP on admission, ST-segment depression on admission, and peak cTnI N0.07 μg/L (within 24 hours), GRACE risk score.
heterogeneity. We conducted a sensitivity analysis based on all-cause mortality. In the sensitivity analyses, the results suggested that the pooled HRs or 95% CI did not reflect significant difference when omitting one of the studies from the analysis. (Figure S1 and S2, Supporting Information).
| Publication bias
Egger test showed that no publication bias was observed (coefficient Two studies were conducted on meta-analysis of the relationship between GDF-15 and the different prognosis of acute coronary syndromes and heart failure separately. One of them, GDF-15 is classified as a categorical variable for statistical analysis, 38 and the other is as a continuous variable. 39 In our meta-analysis, 31 studies were included was proved by experiment that GDF-15 plays a protective role by inhibiting apoptosis, hypertrophy, and adverse remodeling in the injured heart. GDF-15 also participated in the development of cardiac remodeling in HF with a function of counterworking hypertrophy and apoptosis through PI3K-Akt, ERK1/2, and SMAD2/3 signaling pathways. 2 A study of a large sample of AF has identified that GDF-15 is an indicator for the prognosis of major bleeding and death. 33 Owing to the incidence trend of ischemic heart disease, the application of GDF-15 on early diagnosis and prognosis of disease is widely studied.
In an animal model, it was confirmed that GDF-15 played a cardioprotective role. After the occurrence of ischemia-reperfusion (I/R), the expression of GDF-15 was sharply enhanced in the cardiomyocytes as an endogenous protective cytokine against I/R-induced cardiomyocyte apoptosis, possibly through PI3K-Akt-dependent signaling pathways. In addition, it seemed to be mediated by the approach of induction of nitric oxide (NO) synthase-2, production of NO and peroxynitrite formation. Meanwhile, some relevant pro-inflammatory cytokines (interferon-γ and interleukin-1β) involved in the induction of GDF-15 through NO-dependent pathways. 3 Besides, GDF-15, has provided more valuable information for risk stratification and prognosis in CVDs. 11 An epidemiological research demonstrates that GDF-15 levels are associated with carotid artery intima-media thickness, plaque burden, and endothelial dysfunction in elderly individuals, which may provide insight into disparate mechanism of GDF-15 pathophysiology. 40 Some studies included in our meta-analysis demonstrate that GDF-15 has performed well both in identifying stable and unstable CAD and in evaluating the prognosis, and likewise, independent of traditional clinical risk biomarkers, such as troponin T, NT-proBNP, and hs-CRP. 6, 13, 15 To find the potential heterogeneity, we did metaregression analysis and sensitivity analysis to identify conceivable sources of the discrepancy from the studies that reported all-cause mortality as endpoints. Several probable aspects were filtered for the subgroup analyses. Paradoxically, the results of meta-regression analysis and sensitive analysis was failed to elucidate that where the heterogeneity stems from genuinely. It was inexplicit that which was the initiator of the difference. Furthermore, the results of the sensitivity analysis also indicated that the elimination of any study did not make a significant alteration in the pooled HR.
In conclusion, it can be noted that the present study has stated the association between GDF-15 and adverse prognosis of CVDs and all-cause mortality. A large number of research need to be done until GDF-15 could contribute to clinical and bring more valuable information for clinician.
| LIMITATION
We delimit the studies published in the English language as one of the eligible criteria, which may be a limiting factor. First based on prospective study data, the result of our meta-analysis is subject to potential bias. Although potential confounders, such as age, sex, and body mass index have been adjusted in most studies, residual confounding cannot be precluded. Second, some studies of small sample size resulting in extremely strong associations may have an impact on pooled estimates. Third, the characteristics of baseline participants differ across included studies which cause the initial production of heterogeneity.
Fourth, on account of disparate adjusted variables of each study it is arduous to unify the diverse adjustments for all studies. Fifth, a doseeffect relationship between the GDF-15 level and all-cause mortality or adverse cardiac events is failed to be conducted owing to the lack of indispensable data. In addition, the indefinite cutoff point of GDF-15 and the various assay methods may influence the results. The relative small sample sizes of studies attenuate the strength of this metaanalysis. Furthermore, larger numbers of studies are expected to strengthen our results, which may provide more vital information on the diagnosis and prognosis for CVDs.
| CONCLUSION
Elevated GDF-15 may increase risk of all-cause mortality and adverse cardiovascular events. Further and more detailed clinical investigations are needed to conduct to identify whether measurement of FIGURE 3 A, Pooled HR and 95% CI by subgroups (sample size, baseline population, follow-up, and assay method) of the association between growth differentiation factor-15 (GDF-15) levels and all-cause mortality (categorical variable). Black dots represent HRs and bars indicate 95% CIs. B, Pooled HR and 95% CI by subgroups (sample size, baseline population, follow-up, assay method) of the association between GDF-15 levels and all-cause mortality (continuous variable). Black dots represent HRs and bars indicate 95% CIs. CI, confidence interval; HR, hazard ratio; CHD, coronary heart disease; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay GDF-15 can be applied to clinical patients for an effective earlier diagnosis, risk stratification, and prognosis assessment.
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